MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 15 May 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 12 Nov 2008 Actual end date (1 Feb 2008 to May 2008) changed, as reported by ClinicalTrials.gov.
- 23 Sep 2008 Results have been reported at EASD 2008 (44th Annual Meeting of the European Association for the Study of Diabetes).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History